Abstract
The cumulative burden of the COVID-19 virus on the US healthcare system is substantial. To help mitigate this burden, novel solutions including tele-health and dedicated screening facilities have been utilized. However, there is limited data on the efficacy of such models and none assessing patient comfort levels with these changes in health care delivery. The aim of our study was to evaluate patients’ perceptions of a drive through medical treatment system in the setting of the COVID-19 pandemic.
Highlights
BXCL501 is an investigational orally dissolving thin film of the highly selective alpha-2a adrenergic receptor agonist, dexmedetomidine, for sublingual or buccal administration. This secondary analysis of 2 Phase 3 studies of acute agitation in patients with schizophrenia or bipolar disorder evaluated efficacy by baseline agitation severity on both the PANSS-Excited Component (PEC) total and the 5 items making up the PEC
Significant (P < .01) improvements from baseline to 2 hours in PEC total score were observed with BXCL501 vs placebo among subgroups with moderate or severe agitation
Significant (P < .0001) improvements from baseline in each of the 5 components of the PEC were observed with both doses of BXCL501 compared to placebo
Summary
The aim of our study was to evaluate patients’ perceptions of a drive through medical treatment system in the setting of the COVID-19 pandemic
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
